GlaxoSmithKline posts rising Q3 profits

October 26, 2011

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

The London-listed group also hiked its by six percent to 17 pence, and added that it would increase share repurchases this year to £2.3 billion, compared with £2.0 billion previously.

Earnings after taxation increased to £1.378 billion ($2.20 billion, 1.58 billion euros) in the three months to the end of September, compared with £1.288 in the same part of last year, GSK said in a results statement.

Sales grew six percent to £6.992 billion in the reporting period.

"The breadth and mix of GSK's product and geographic portfolio is helping the group to mitigate economic volatility," chief executive Andrew Witty said in the earnings release.

"However, the environment for pharmaceutical and consumer products remains challenging."

In early afternoon deals, GSK's share price rose 0.47 percent to 1,388.50 pence on London's FTSE 100 index of leading companies, which was 0.23 percent higher at 5,538.16 points.

"GlaxoSmithkline's third quarter numbers may not be the most exciting, but the pharmaceutical giant continues to go from strength to strength," said ETX Capital senior trader Manoj Ladwa.

"Despite reporting in-line with analyst expectations, investors will be encouraged by the 6.0-percent hike in dividend and shifting the share buy-back programme up a notch."

The company was last year plagued by exceptional legal charges linked to its former diabetes drug Avandia, which has been pulled from European shelves on fears that it increased the risk of heart attack and strokes.

GSK was rocked in September 2010 when the European Union medicines regulator decided to ban Avandia. Regulators also restricted its availability in the United States.

The EU pulled Avandia owing to concerns over its active substance rosiglitazone. It decided also to halt the sale of Glaxo's other diabetes drugs, Avandamet and Avaglim, since they too contained rosiglitazone.

Explore further: GlaxoSmithKline reports return to profit in second quarter

Related Stories

GlaxoSmithKline reports return to profit in second quarter

July 26, 2011
British drugmaker GlaxoSmithKline posted net profit of more than £1.1 billion in the second quarter on Tuesday following a loss during the equivalent three-month period in 2010.

IBM raises guidance, beats Street estimates

July 18, 2011
IBM Corp. raised its income guidance for the year on Monday as earnings in the latest quarter increased 8 percent because of growth in all three of its major product categories.

Drugs firm GSK eyes India acquisitions: chief executive

October 3, 2011
British drugmaker GlaxoSmithKline is in the market to buy assets in India at a total cost of up to $2.0 billion (1.5 billion euros), its chief executive said in an interview published on Monday.

Taiwan's Hon Hai 2Q profit down 23%

August 31, 2011
Taiwan tech giant Hon Hai Precision, the world's biggest contract electronics maker, said Wednesday net profit fell 23 percent in the three months to June mainly due to a tax on retained earnings.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

hush1
not rated yet Oct 26, 2011
And the 'glitch' in Austria?
Surely you must have something for amnesia?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.